Drug intelligence / Profile preview

Amibargeqi-18

Development stage: Unknown
Lead developer: Amylyx Pharmaceuticals
Administration: Oral

Overview

Amibargeqi-18 is referenced as an orally administered medication, described in a clinical trial context as "13–15 pills, taken orally after dinner." It appears to be compared against a Mongolian medicine simulation agent (Tonglaga 601) in a controlled group. No further pharmacological, mechanistic, or chemical information is available from the provided sources. There are no details on its mechanism of action, molecular structure, class, or therapeutic indication beyond its use in this specific trial setting[4].

Brand names: Amibargeqi-18Amibargeqi18Amibargeqi 18
Other names: Amibargeqi-18Amibargeqi18Amibargeqi 18

Beyond the preview

Go deeper on Amibargeqi-18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amibargeqi-18.

Explore the full profile